{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T20:25:26Z","timestamp":1795206326611,"version":"4.10.3"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T00:00:00Z","timestamp":1763769600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T00:00:00Z","timestamp":1767052800000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-15371-7","type":"journal-article","created":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T05:45:23Z","timestamp":1763790323000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["CombiCoR-Vax trial: study protocol for a phase II, single-arm, multicenter trial of sequential pembrolizumab plus dendritic cell vaccine followed by trifluridine\/tipiracil and bevacizumab in refractory microsatellite-stable metastatic colorectal cancer"],"prefix":"10.1186","volume":"25","author":[{"given":"Alessandro","family":"Passardi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco Giulio","family":"Sullo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Bittoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Matteucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"De Rosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Bulgarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcella","family":"Tazzari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimiliano","family":"Petrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Scarpi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Testoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Miserocchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ottavia","family":"Tartagni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Zani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Laura","family":"Iaia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Toma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo Giuseppe","family":"Viola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Teresa","family":"Mita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emiliano","family":"Tamburini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Ridolfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,22]]},"reference":[{"key":"15371_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"15371_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel RL, Miller KD, Fuchs HE, Biller LH, Schrag D. Cancer Stat Clin. 2022;72:7\u2013332.","journal-title":"Cancer Stat Clin"},{"key":"15371_CR3","unstructured":"Diagnosis and Treatment of Metastatic Colorectal Cancer. A Review | Oncology | JAMA | JAMA Network . [citato 17 marzo 2025]. Disponibile su: https:\/\/jamanetwork-com.bibliosan.idm.oclc.org\/journals\/jama\/fullarticle\/2776334."},{"issue":"1","key":"15371_CR4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41698-022-00342-z","volume":"7","author":"FA Zeineddine","year":"2023","unstructured":"Zeineddine FA, Zeineddine MA, Yousef A, Gu Y, Chowdhury S, Dasari A, et al. Survival improvement for patients with metastatic colorectal cancer over Twenty years. Npj Precis Oncol 13 Febbraio. 2023;7(1):1\u20139.","journal-title":"Npj Precis Oncol 13 Febbraio"},{"key":"15371_CR5","doi-asserted-by":"publisher","unstructured":"Annals of Oncology. (2023) 34 (suppl_2): S410-S457. https:\/\/doi.org\/10.1016\/S0923-7534(23)01935-X.","DOI":"10.1016\/S0923-7534(23)01935-X"},{"key":"15371_CR6","unstructured":"Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT). an international, multicentre, randomised, placebo-controlled, phase 3 trial - The Lancet. [citato 2 settembre 2024]. Disponibile su: https:\/\/www.thelancet.com\/journals\/lancet\/article\/PIIS0140-6736(12)61900-X\/abstract."},{"key":"15371_CR7","doi-asserted-by":"crossref","unstructured":"Mayer RJ, Cutsem EV, Falcone A, Yoshino T, Garcia-Carbonero R, Mizunuma N et al. Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer. N Engl J Med. 14 maggio. 2015;372(20):1909\u201319.","DOI":"10.1056\/NEJMoa1414325"},{"key":"15371_CR8","doi-asserted-by":"crossref","unstructured":"Prager GW, Taieb J, Fakih M, Ciardiello F, Cutsem EV, Elez E et al. Trifluridine\u2013Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer. N Engl J Med. 3 maggio. 2023;388(18):1657\u201367.","DOI":"10.1056\/NEJMoa2214963"},{"key":"15371_CR9","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41568-019-0116-x","volume":"19","author":"JJ Havel","year":"2019","unstructured":"Havel JJ, Chowell D, Chan TA. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat Rev Cancer. 2019;19:133\u201350.","journal-title":"Nat Rev Cancer"},{"key":"15371_CR10","first-page":"100442","volume":"28","author":"G Arrichiello","year":"2021","unstructured":"Arrichiello G, Poliero L, Borrelli C. Immunotherapy in colorectal cancer: is the Long-Awaited revolution finally happening? Cancer treat. Res Commun. 2021;28:100442.","journal-title":"Res Commun"},{"key":"15371_CR11","doi-asserted-by":"publisher","unstructured":"Matteucci L, Bittoni A, Gallo G, Ridolfi L, Passardi A. Immunocheckpoint Inhibitorsin Microsatellite-Stable or Proficient Mismatch Repair Metastatic Colorectal Cancer: Are WeEntering a New Era?. Cancers (Basel). 2023;15(21):5189. https:\/\/doi.org\/10.3390\/cancers15215189.","DOI":"10.3390\/cancers15215189"},{"issue":"ue 7","key":"15371_CR12","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/S1470-2045(22)00274-1","volume":"23","author":"C Antoniotti","year":"2022","unstructured":"Antoniotti C, Rossini D, Pietrantonio F. Upfront FOLFOXIRI plus bevacizumab with or without Atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet Oncol. 2022;23(ue 7):876\u201387.","journal-title":"Lancet Oncol"},{"key":"15371_CR13","doi-asserted-by":"crossref","unstructured":"Tougeron D. Pembrolizumab in combination with xelox and bevacizumab in patients with microsatellite stable (pMMR\/MSS) metastatic colorectal cancer (mCRC) and a high immune infiltrate: A proof of concept study. In: Preliminary results of FFCD 1703 POCHI trial Annals of Oncology. 2024.","DOI":"10.1016\/j.annonc.2024.06.005"},{"key":"15371_CR14","doi-asserted-by":"publisher","unstructured":"Morano F, Raimondi A, Pagani F, et al. Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O6-Methylguanine-DNA Methyltransferase-Silenced Metastatic Colorectal Cancer: The MAYA Trial. J Clin Oncol. 2022;40(14):1562\u20131573. https:\/\/doi.org\/10.1200\/JCO.21.02583.","DOI":"10.1200\/JCO.21.02583"},{"key":"15371_CR15","doi-asserted-by":"publisher","unstructured":"Adamik J, Butterfield LH. What's next for cancer vaccines. Sci Transl Med. 2022;14(670):eabo4632. https:\/\/doi.org\/10.1126\/scitranslmed.abo4632.","DOI":"10.1126\/scitranslmed.abo4632"},{"key":"15371_CR16","doi-asserted-by":"publisher","unstructured":"Aldahlawi AM, Abdullah ST. Dendritic Cell-Based Immunotherapies and their Potential use in Colorectal Cancer Immunotherapy. J Microsc Ultrastruct. 2021;10(3):107-113. https:\/\/doi.org\/10.4103\/jmau.jmau_20_21.","DOI":"10.4103\/jmau.jmau_20_21"},{"issue":"4","key":"15371_CR17","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1158\/1078-0432.CCR-05-2059","volume":"12","author":"PM Arlen","year":"2006","unstructured":"Arlen PM, Gulley JL, Parker C, Skarupa L, Pazdur M, Panicali D, et al. A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clin Cancer Res 17 Febbraio. 2006;12(4):1260\u20139.","journal-title":"Clin Cancer Res 17 Febbraio"},{"issue":"16","key":"15371_CR18","doi-asserted-by":"publisher","first-page":"5316","DOI":"10.1158\/1078-0432.CCR-04-0497","volume":"10","author":"CJ Wheeler","year":"2004","unstructured":"Wheeler CJ, Das A, Liu G, Yu JS, Black KL. Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination. Clin Cancer Res Off J Am Assoc Cancer Res 15 Agosto. 2004;10(16):5316\u201326.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res 15 Agosto"},{"key":"15371_CR19","doi-asserted-by":"publisher","unstructured":"de Rosa F, Ridolfi L, Fiammenghi L, et al. Dendritic cell vaccination for metastatic melanoma: a 14-year monoinstitutional experience. Melanoma Res. 2017;27(4):351\u20137. https:\/\/doi.org\/10.1097\/CMR.0000000000000356.","DOI":"10.1097\/CMR.0000000000000356"},{"key":"15371_CR20","first-page":"504979","volume":"2010","author":"L Ridolfi","year":"2010","unstructured":"Ridolfi L, Petrini M, Fiammenghi L. Unexpected high response rate to traditional therapy after dendritic cell-based vaccine in advanced melanoma: update of clinical outcome and subgroup analysis. Clin Dev Immunol. 2010;2010:504979.","journal-title":"Clin Dev Immunol"},{"key":"15371_CR21","doi-asserted-by":"publisher","unstructured":"Prager GW, Taieb J, Fakih M, et al. Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer. N Engl J Med. 2023;388(18):1657\u20131667. https:\/\/doi.org\/10.1056\/NEJMoa2214963.","DOI":"10.1056\/NEJMoa2214963"},{"issue":"5","key":"15371_CR22","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/S1470-2045(22)00197-8","volume":"23","author":"LA Diaz","year":"2022","unstructured":"Diaz LA, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt C, et al. Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study. Lancet Oncol Maggio. 2022;23(5):659\u201370.","journal-title":"Lancet Oncol Maggio"},{"key":"15371_CR23","doi-asserted-by":"crossref","unstructured":"Andre T, Elez E, Van Cutsem E, Jensen LH, Bennouna J, Mendez G et al. Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high\/mismatch repair-deficient (MSI-H\/dMMR) metastatic colorectal cancer (mCRC): first results of the checkmate 8HW study. J Clin Oncol 20 gennaio 2024;42(3_suppl):LBA768\u2013768.","DOI":"10.1200\/JCO.2024.42.3_suppl.LBA768"},{"issue":"15","key":"15371_CR24","doi-asserted-by":"publisher","first-page":"6171","DOI":"10.1158\/0008-5472.CAN-10-0153","volume":"70","author":"RK Shrimali","year":"2010","unstructured":"Shrimali RK, Yu Z, Theoret MR, Chinnasamy D, Restifo NP, Rosenberg SA. Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res 28 Luglio. 2010;70(15):6171\u201380.","journal-title":"Cancer Res 28 Luglio"},{"issue":"4","key":"15371_CR25","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1038\/onc.2009.356","volume":"29","author":"A Tesniere","year":"2010","unstructured":"Tesniere A, Schlemmer F, Boige V, Kepp O, Martins I, Ghiringhelli F, et al. Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene Gennaio. 2010;29(4):482\u201391.","journal-title":"Oncogene Gennaio"},{"issue":"1","key":"15371_CR26","first-page":"1","volume":"39","author":"DS Chen","year":"2013","unstructured":"Chen DS, Mellman I. Oncology Meets immunology: the Cancer-Immunity cycle. Immun 25 Luglio. 2013;39(1):1\u201310.","journal-title":"Immun 25 Luglio"},{"issue":"1","key":"15371_CR27","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1093\/annonc\/mdt349","volume":"25","author":"AG Duffy","year":"2014","unstructured":"Duffy AG, Greten TF. Immunological off-target effects of standard treatments in Gastrointestinal cancers. Ann Oncol 1 Gennaio. 2014;25(1):24\u201332.","journal-title":"Ann Oncol 1 Gennaio"},{"issue":"8","key":"15371_CR28","doi-asserted-by":"publisher","first-page":"3052","DOI":"10.1158\/0008-5472.CAN-09-3690","volume":"70","author":"J Vincent","year":"2010","unstructured":"Vincent J, Mignot G, Chalmin F, Ladoire S, Bruchard M, Chevriaux A, et al. 5-Fluorouracil selectively kills Tumor-Associated Myeloid-Derived suppressor cells resulting in enhanced T Cell\u2013Dependent antitumor immunity. Cancer Res 14 Aprile. 2010;70(8):3052\u201361.","journal-title":"Cancer Res 14 Aprile"},{"issue":"19","key":"15371_CR29","doi-asserted-by":"publisher","first-page":"3089","DOI":"10.1200\/JCO.2005.04.5252","volume":"24","author":"EJ Small","year":"2006","unstructured":"Small EJ, Schellhammer PF, Higano CS. Placebo-controlled phase III trial of Immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol. 2006;24(19):3089\u201394.","journal-title":"J Clin Oncol"},{"issue":"3","key":"15371_CR30","first-page":"201","volume":"12","author":"J Kleponis","year":"2015","unstructured":"Kleponis J, Skelton R, Zheng L. Fueling the engine and releasing the break: combinational therapy of cancer vaccines and immune checkpoint inhibitors. Cancer Biol Med Settembre. 2015;12(3):201\u20138.","journal-title":"Cancer Biol Med Settembre"},{"key":"15371_CR31","doi-asserted-by":"publisher","unstructured":"Jia W, Shen X, Guo Z, Cheng X, Zhao R. The future of cancer vaccines against colorectal cancer. Expert Opin Biol Ther. 2024;24(4):269\u2013284. https:\/\/doi.org\/10.1080\/14712598.2024.2341744.","DOI":"10.1080\/14712598.2024.2341744"},{"key":"15371_CR32","doi-asserted-by":"publisher","unstructured":"Espa\u00f1ol-Rego M, Fern\u00e1ndez-Martos C, Elez E, et al. A Phase I-II multicenter trial with Avelumab plus autologous dendritic cell vaccine in pre-treated mismatch repair-proficient (MSS) metastatic colorectal cancer patients; GEMCAD 1602 study. Cancer Immunol Immunother. 2023;72(4):827\u2013840. https:\/\/doi.org\/10.1007\/s00262-022-03283-5.","DOI":"10.1007\/s00262-022-03283-5"},{"issue":"11","key":"15371_CR33","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1158\/2326-6066.CIR-14-0076","volume":"2","author":"B Farsaci","year":"2014","unstructured":"Farsaci B, Donahue RN, Coplin MA, Grenga I, Lepone LM, Molinolo AA, et al. Immune consequences of decreasing tumor vasculature with antiangiogenic tyrosine kinase inhibitors in combination with therapeutic vaccines. Cancer Immunol Res 2 Novembre. 2014;2(11):1090\u2013102.","journal-title":"Cancer Immunol Res 2 Novembre"},{"key":"15371_CR34","doi-asserted-by":"publisher","first-page":"4367","DOI":"10.1007\/s13277-015-3957-2","volume":"37","author":"T Lin","year":"2016","unstructured":"Lin T, Song C, Chuo DY. Clinical effects of autologous dendritic cells combined with cytokine-induced killer cells followed by chemotherapy in treating patients with advanced colorectal cancer: a prospective study. Tumor Biol. 2016;37:4367\u201372.","journal-title":"Tumor Biol"},{"key":"15371_CR35","doi-asserted-by":"publisher","first-page":"5363","DOI":"10.2147\/CMAR.S173201","volume":"10","author":"X Zhou","year":"2018","unstructured":"Zhou X, Mo X, Qiu J, et al. Chemotherapy combined with dendritic cell vaccine and cytokine-induced killer cells in the treatment of colorectal carcinoma: a meta-analysis. Cancer Manag Res. 2018;10:5363\u201372. https:\/\/doi.org\/10.2147\/CMAR.S173201.","journal-title":"Cancer Manag Res"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15371-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-15371-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15371-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T01:54:53Z","timestamp":1767059693000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-025-15371-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,22]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["15371"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-15371-7","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,22]]},"assertion":[{"value":"11 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study (Protocol version 2.0, October 3rd 2024) was approved by the National Ethics Committee for Advanced Therapy (CEN ATMP) and registered on Clinicaltrials.gov (NCT06522919). The study protocol has been approved by all participant centers. All personnel involved in conducting the current study shall abide by the latest Declaration of Helsinki and Ethical Guidelines for Clinical Studies. Written informed consent will be obtained from all participants to the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1921"}}